aTyr Pharma, Inc. filed a Form 8-K on November 13, 2026, disclosing that Nasdaq notified the company it had regained compliance with the minimum closing bid price requirement after its common stock closed at $1.00 per share or greater for 10 consecutive business days.

Key Highlights

  • Compliance Regained: Nasdaq staff confirmed aTyr Pharma has satisfied Listing Rule 5550(a)(2), the minimum closing bid price requirement.
  • Qualifying Period: The company's common stock closed at $1.00 per share or greater for 10 consecutive business days, from October 30, 2026 to November 12, 2026.
  • Original Deficiency Notice: The deficiency process began December 4, 2025, when Nasdaq notified the company its bid price had closed below $1.00 for the prior 30 consecutive business days.
  • Second Compliance Period: On June 3, 2026, Nasdaq granted an additional 180-day period, until November 30, 2026, for the company to regain compliance.
  • No Outstanding Deficiencies: According to the filing, "the Company has no outstanding deficiency notices from Nasdaq" as of November 13, 2026.

aTyr Pharma Closes Out Nasdaq Deficiency Process After 10-Day Bid Price Recovery

aTyr Pharma, Inc. (NASDAQ:ATYR) disclosed in a Form 8-K filed November 13, 2026 that Nasdaq's listing qualifications staff determined the company had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share for continued listing on The Nasdaq Capital Market.

According to the filing, the deficiency process began on December 4, 2025, when Nasdaq notified the company that the bid price of its common stock had closed below $1.00 per share for the preceding 30 consecutive business days. The filing notes that the original notice "had no immediate effect on the listing of the Company's common stock." On June 3, 2026, Nasdaq granted the company a second 180-day compliance window, running until November 30, 2026, based on the company meeting continued listing requirements for market value of publicly held shares and all other initial listing standards, with the exception of the minimum bid price requirement.

On November 13, 2026, the company received a letter from Nasdaq staff confirming that the closing bid price had remained at $1.00 per share or greater for 10 consecutive business days between October 30, 2026 and November 12, 2026, satisfying the rule. The filing states the company has no outstanding deficiency notices from Nasdaq as of that date. The 8-K was signed by Brandon Yaras, Chief Financial Officer of aTyr Pharma, Inc.

What Was Disclosed

aTyr Pharma filed an 8-K reporting that Nasdaq confirmed the company regained compliance with the minimum bid price listing rule, closing a deficiency process that began in December 2025 and concluding with a 10-day qualifying period ending November 12, 2026.